

Algorithm for WHO Recommended Diagnostics (WRDs) (MGIT Culture)

**Module 1: WHO recommended TB diagnostic assays &
algorithms**

Date:

By:

**Uganda Supranational Reference
Laboratory**

Content Outline

- Materials for MGIT Culture
- WHO endorsed TB diagnostic techniques until 2017





Materials

BD MGIT


WHO's recommended techniques for diagnosing TB: until 2017

- **Microscopy**
 - Conventional light microscopy
 - Light-emitting diode fluorescent microscopy
- **Culture**
 - Culture on solid media
 - Commercial liquid culture systems and rapid speciation
- **Drug-susceptibility testing**
 - DST first-line anti-TB agents
 - DST for second-line anti-TB agents
 - Non-commercial methods
- **Molecular testing**
 - LPA (first and second-line)
 - TB-LAMP
 - Xpert MTB/RIF assay (Ultra+others)
- **LF-LAM Urine test for PLHIV**




- Available at: <http://www.who.int/tb/dots/laboratory/policy/en>


Placement of different tests at the levels of laboratory sophistication



Flow Chart 1: General Algorithm MGIT 960 Cultures




Flow Chart 2: Contaminated MGIT Cultures




MG/PP/001, Version 1.0, Effective date: 01-Jun-2019


Flow Chart 2A: Suspected MOTT Cultures



Flow Chart 3: MGIT "Early Positive" Cultures (ZN/BAP negative)



Flow Chart 3: MGIT "Early Positive" Cultures (ZN/BAP negative)



Group exercise-10 minutes

1. List all the WHO approved TB diagnostic tests that you know
2. Identify the role of each of those tests in the MTB MGIT culture diagnostic algorithm.

Assessment

1. What is the role of culture & phenotypic DST in the diagnosis & management of TB with the advent of the rapid and more sensitive TB diagnostic assays?

Summary

1. Laboratories play a **significant role** under the End TB Strategy
2. Increasing access to **rapid detection** of TB and reaching **universal access to DST** will require major efforts
3. **Future diagnostics** will play a role in reaching targets of End TB Strategy, but we also need to make the **best use** of the currently available diagnostics
4. **Multi-disease testing platforms** will provide opportunities for laboratory integration
5. **Connectivity** provides opportunities for improved quality assurance and patient care
6. Adoption of **WHO policy guidance** on new TB diagnostics combined with use of **GLI implementation guidance** can help countries reach the targets of the End TB Strategy for laboratory strengthening

References

- www.gliafricatb.org
- www.who.int/tb
- <http://www.who.int/tb/publications/molecular-test-resistance/en>
- <http://www.who.int/tb/dots/laboratory/policy/en>

Acknowledgments

